Table 2.
Intervention model parameters. CrI credible interval
| Parameter | Mean value (95% CI where applicable) | Reference | |
|---|---|---|---|
| Palivizumab | |||
| Delay between administration and protection (days) | Immediate (fixed) | [16] | |
| ωpal | Average period of protection (days) | 150 (fixed) | [16] |
| epal | Efficacy on VHR infants (%) | 33.8 (0.0–66.6)1 | [16] |
| Long-acting monoclonal antibodies | |||
| Delay between administration and protection (days) | Immediate (fixed) | [4] | |
| ωmab | Average period of protection (days) | 275 (fixed) | [4] |
| eSmab | Efficacy against symptomatic infection (%) | 70.1 (52.3–81.0)2 | [37] |
| eHmab | Efficacy against hospitalisation (%) | 78.4 (51.9–90.3)3 | [37] |
| Childhood/elderly vaccine | |||
| dvac | Delay between administration and protection (days) | 11.4 (2.8–22.1)4 | [38] |
| ω | Average period of protection (days) | Same as post-infection immunity (1/ω) | [38] |
| evac | Efficacy against all infections (%) | 83.0 (75.0–88.0)5 | [38] |
| Novavax vaccine | |||
| d2mat | Average period of protection (days) | 133.5 (119.6–146.1) | Same as maternally derived immunity |
| eSmat | Efficacy against symptomatic infection (%) | 41.4 (4.1–64.2)6 | [5] |
| eHmat | Efficacy against hospitalisations (%) | 53.5 (23.0–71.9)7 | [5] |
Fitted distributions
1Gamma (3.7623, 0.0898)
2W(11.898, 0.732)
3W(11.611, 0.819)
4W(2.42, 12.87)
5W(31.464, 0.845)
6W(3.327, 0.461)
7W(5.354, 0.580)